SecBot SecBot
Biotech Drug Report Generated Oct 29, 2026

LAGEVRIO

MRK·Merck & Co., Inc.
NEUTRAL
Drug Impact Rating4/10
Trial phase
EUA (Emergency Use Authorization) / Marketed
Time to market
Already on the market under EUA since December 2021. Must obtain full FDA approval by June 29, 2027 or lose U.S. marketing authorization.
Why 4/10
LAGEVRIO is an EUA-authorized drug with no pending PDUFA date or pivotal readout. The next hard catalyst is the June 29, 2027 EUA termination deadline (~8 months away), but the drug represents less than 1% of Merck's $66B+ annual revenue, so even a binary regulatory outcome would not materially move MRK shares.
Actionable Insight NEUTRAL

The next hard catalyst for LAGEVRIO is the June 29, 2027 deadline when the COVID-19 EUA declaration terminates. Merck must obtain full FDA approval (an NDA) by that date or lose the ability to market LAGEVRIO in the U.S. However, with sales already collapsing to $138M in Q3 2026 (down 64% YoY) and the drug representing a trivial fraction of Merck's $66B+ annual revenue, this binary regulatory event is unlikely to move MRK shares materially. Watch for any Merck announcement of an NDA submission for molnupiravir, which would signal intent to pursue full approval before the deadline.

Price Chart

Loading chart...

Executive Summary

LAGEVRIO (molnupiravir) is Merck's oral antiviral COVID-19 treatment, authorized under FDA Emergency Use Authorization (EUA) since December 2021. It has never received full FDA approval. On June 30, 2026, HHS announced the COVID-19 EUA declaration will terminate on June 29, 2027, meaning LAGEVRIO must obtain full NDA approval by that date or lose U.S. market access. Meanwhile, sales are in steep decline: Q3 2026 revenue was $138M (down 64% YoY), and the drug faces strong competition from Pfizer's fully-approved Paxlovid. For Merck, a $346B market cap company with $66B+ in annual revenue driven by Keytruda, Gardasil, and Winrevair, LAGEVRIO is a negligible contributor (less than 1% of sales) and its decline does not materially affect the investment thesis.

How It Works

Molnupiravir is an oral antiviral pill that works by causing the virus to make many copying errors when it tries to replicate, essentially forcing the virus to mutate itself to death. It is taken by mouth as capsules and is designed for early treatment of mild-to-moderate COVID-19 in high-risk adults.

Trial Status

LAGEVRIO is commercially available under FDA EUA. The Phase 3 MOVe-AHEAD trial evaluating it for post-exposure prophylaxis failed to show a statistically significant reduction in COVID-19 risk. No new pivotal trials are actively recruiting. The key regulatory overhang is the June 29, 2027 EUA termination deadline.

The Two-Sided Case

▲ Bull Case4
LAGEVRIO remains an available oral treatment option for high-risk COVID-19 patients who cannot take Paxlovid due to drug interactions, maintaining a niche market position.
The EUA termination deadline of June 29, 2027 gives Merck roughly 8 months to pursue full FDA approval, which could extend the product's commercial life.
Merck's massive diversified portfolio (Keytruda, Gardasil, Winrevair, Animal Health) means LAGEVRIO's declining sales do not threaten the company's overall financial health.
Analyst consensus on MRK is bullish: 26 of 27 analysts rate it Buy/Strong Buy, with a mean price target of $159.76 implying 13.4% upside from the current $140.93.
▼ Bear Case5
Sales are collapsing rapidly: Q3 2026 LAGEVRIO sales were $138M, down 64% year-over-year from $383M in Q3 2025, and Q1 2026 was just $28M.
The drug still lacks full FDA approval. It operates only under Emergency Use Authorization (EUA), which HHS has announced will terminate on June 29, 2027. If Merck cannot obtain full NDA approval by then, LAGEVRIO cannot be marketed in the U.S.
Pfizer's Paxlovid (nirmatrelvir/ritonavir) has full FDA approval and is the market leader in oral COVID-19 antivirals, putting LAGEVRIO at a competitive disadvantage.
LAGEVRIO's efficacy is modest compared to Paxlovid; the Phase 3 MOVe-AHEAD trial for post-exposure prophylaxis failed to show a statistically significant reduction in COVID-19 risk.
As a tiny fraction of Merck's total revenue (less than 1%), even a complete loss of LAGEVRIO sales would have negligible impact on MRK's financials.

Upcoming Catalysts

  • June 29, 2027: Deadline for COVID-19 drug EUA termination. Merck must obtain full FDA approval (NDA) by this date or LAGEVRIO loses U.S. market access.
  • Any announcement of an NDA submission for molnupiravir would signal intent to pursue full approval before the EUA deadline.

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Merck & Co., Inc. 8-K MRK ·Originating report

Sources · 12

Hover a chip for the title
1 merck.com2 lagevrio.com3 hhs.gov4 federalregister.gov5 bioplayground.com6 finviz.com7 opencapital.sh8 merck.com9 cnbc.com10 merck.com11 merck.com12 merck.com